Literature DB >> 29948617

The Histone Acetylation Modifications of Breast Cancer and their Therapeutic Implications.

Pingping Guo1, Wenqi Chen1, Huiyu Li1, Meiying Li1, Lisha Li2.   

Abstract

The histone acetylation modifications (HAMs) influence a large number of cellular functions. They are mediated through histone acetyltransferase (HAT) and histone deacetylase (HDAC). Nowadays, people have realized that HAMs are crucial for development and prognosis of breast cancer. Investigations about abnormal HAMs in breast cancer focus on initiating molecular mechanisms in breast cancer development, identification of new biomarkers to predict breast cancer aggressiveness and the therapeutic potential. As HAMs are reversible, breast cancer may be treated by restoring HAMs to normal levels. Indeed, some HDAC inhibitors have been approved by the US Food and Drug Administration to treat certain cancers. Furthermore, HAT inhibitors, HAT activators and HDAC activators may also be used as drugs to treat breast cancer.

Entities:  

Keywords:  Breast cancer; Histone acetylation; Histone deacetylation; Therapy

Mesh：

Substances：

Year:  2018        PMID： 29948617     DOI： 10.1007/s12253-018-0433-5

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN： 1219-4956            Impact factor:   3.201


  47 in total

1.  Genetic alterations of KDM4 subfamily and therapeutic effect of novel demethylase inhibitor in breast cancer.

Authors:  Qin Ye; Andreana Holowatyj; Jack Wu; Hui Liu; Lihong Zhang; Takayoshi Suzuki; Zeng-Quan Yang
Journal:  Am J Cancer Res       Date:  2015-03-15       Impact factor: 6.166

2.  Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat).

Authors:  Makoto Kubo; Noriko Kanaya; Karineh Petrossian; Jingjing Ye; Charles Warden; Zheng Liu; Reiki Nishimura; Tomofumi Osako; Masayuki Okido; Kazuo Shimada; Masato Takahashi; Peiguo Chu; Yate-Ching Yuan; Shiuan Chen
Journal:  Breast Cancer Res Treat       Date:  2012-11-18       Impact factor: 4.872

Review 3.  The increasing roles of epigenetics in breast cancer: Implications for pathogenicity, biomarkers, prevention and treatment.

Authors:  Clémence Basse; Michel Arock
Journal:  Int J Cancer       Date:  2014-12-01       Impact factor: 7.396

4.  A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.

Authors:  Jangsoon Lee; Chandra Bartholomeusz; Oula Mansour; Juliane Humphries; Gabriel N Hortobagyi; Peter Ordentlich; Naoto T Ueno
Journal:  Breast Cancer Res Treat       Date:  2014-06-12       Impact factor: 4.872

5.  The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression.

Authors:  Marion A Salvador; Julien Wicinski; Olivier Cabaud; Yves Toiron; Pascal Finetti; Emmanuelle Josselin; Hélène Lelièvre; Laurence Kraus-Berthier; Stéphane Depil; François Bertucci; Yves Collette; Daniel Birnbaum; Emmanuelle Charafe-Jauffret; Christophe Ginestier
Journal:  Clin Cancer Res       Date:  2013-10-18       Impact factor: 12.531

6.  Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.

Authors:  Ahrum Min; Seock-Ah Im; Debora Keunyoung Kim; Sang-Hyun Song; Hee-Jun Kim; Kyung-Hun Lee; Tae-Yong Kim; Sae-Won Han; Do-Youn Oh; Tae-You Kim; Mark J O'Connor; Yung-Jue Bang
Journal:  Breast Cancer Res       Date:  2015-03-07       Impact factor: 6.466

7.  Loss of histone H4K20 trimethylation predicts poor prognosis in breast cancer and is associated with invasive activity.

Authors:  Yuhki Yokoyama; Ayaka Matsumoto; Miki Hieda; Yoshimi Shinchi; Eri Ogihara; Mai Hamada; Yu Nishioka; Hiroshi Kimura; Katsuhide Yoshidome; Masahiko Tsujimoto; Nariaki Matsuura
Journal:  Breast Cancer Res       Date:  2014-06-22       Impact factor: 6.466

8.  Histone acetyltransferase inhibitors block neuroblastoma cell growth in vivo.

Authors:  J M Gajer; S D Furdas; A Gründer; M Gothwal; U Heinicke; K Keller; F Colland; S Fulda; H L Pahl; I Fichtner; W Sippl; M Jung
Journal:  Oncogenesis       Date:  2015-02-09       Impact factor: 7.485

Review 9.  Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.

Authors:  Fahimeh Falahi; Michel van Kruchten; Nadine Martinet; Geke A P Hospers; Marianne G Rots
Journal:  Breast Cancer Res       Date:  2014-07-29       Impact factor: 6.466

Review 10.  Male breast cancer: genetics, epigenetics, and ethical aspects.

Authors:  P Rizzolo; V Silvestri; S Tommasi; R Pinto; K Danza; M Falchetti; M Gulino; P Frati; L Ottini
Journal:  Ann Oncol       Date:  2013-11       Impact factor: 32.976
View more
  21 in total

1.  Nicotinamide Phosphoribosyltransferase (NAMPT) Is a New Target of Antitumor Agent Chidamide.

Authors:  Ying Wu; Lei Wang; Yahui Huang; Shuqiang Chen; Shanchao Wu; Guoqiang Dong; Chunquan Sheng
Journal:  ACS Med Chem Lett       Date:  2019-12-13       Impact factor: 4.345

Review 2.  The Essential Role of Epigenetic Modifications in Neurodegenerative Diseases with Dyskinesia.

Authors:  Zhipeng Qi; Jiashuo Li; Minghui Li; Xianchao Du; Lei Zhang; Shuang Wang; Bin Xu; Wei Liu; Zhaofa Xu; Yu Deng
Journal:  Cell Mol Neurobiol       Date:  2021-08-12       Impact factor: 4.231

Review 3.  Epigenetic Therapeutics Targeting NRF2/KEAP1 Signaling in Cancer Oxidative Stress.

Authors:  Shunhao Zhang; Sining Duan; Zhuojun Xie; Wanlin Bao; Bo Xu; Wenbin Yang; Lingyun Zhou
Journal:  Front Pharmacol       Date:  2022-06-09       Impact factor: 5.988

Review 4.  Epigenetic Aspects and Prospects in Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

5.  Histone deacetylase inhibitors reinforce the phenotypical markers of breast epithelial or mesenchymal cancer cells but inhibit their migratory properties.

Authors:  Adolfo Rivero-Muller; Andrzej Stepulak; Anna Wawruszak; Ewelina Gumbarewicz; Estera Okon; Witold Jeleniewicz; Jakub Czapinski; Marta Halasa; Karolina Okla; Jolanta Smok-Kalwat; Artur Bocian
Journal:  Cancer Manag Res       Date:  2019-09-13       Impact factor: 3.989

Review 6.  Epigenetic Dysregulation at the Crossroad of Women's Cancer.

Authors:  Rakesh Kumar; Aswathy Mary Paul; Pranela Rameshwar; M Radhakrishna Pillai
Journal:  Cancers (Basel)       Date:  2019-08-16       Impact factor: 6.639

7.  In silico predictions on the possible mechanism of action of selected bioactive compounds against breast cancer.

Authors:  Aliyu Muhammad; Babangida Sanusi Katsayal; Gilead Ebiegberi Forcados; Ibrahim Malami; Ibrahim Babangida Abubakar; Amina Isah Kandi; Adam Muntaka Idris; Sabi'u Yusuf; Salihu Muktar Musa; Nagedu Monday; Zak-Wan Sidi Umar
Journal:  In Silico Pharmacol       Date:  2020-11-09

8.  Silencing of CREB Inhibits HDAC2/TLR4/NF-κB Cascade to Relieve Severe Acute Pancreatitis-Induced Myocardial Injury.

Authors:  Longfei Pan; Zequn Niu; Yanxia Gao; Liming Wang; Zhong Liu; Jie Liu; Jiangli Sun; Honghong Pei
Journal:  Inflammation       Date:  2021-03-16       Impact factor: 4.092

9.  17‑AAG synergizes with Belinostat to exhibit a negative effect on the proliferation and invasion of MDA‑MB‑231 breast cancer cells.

Authors:  Yu Zuo; Heng Xu; Zhifeng Chen; Fengmin Xiong; Bei Zhang; Kaixian Chen; Hualiang Jiang; Cheng Luo; Hao Zhang
Journal:  Oncol Rep       Date:  2020-03-26       Impact factor: 3.906

10.  Elevated expression of HDAC6 in clinical peritoneal dialysis patients and its pathogenic role on peritoneal angiogenesis.

Authors:  Yingfeng Shi; Jun Ni; Min Tao; Xiaoyan Ma; Yi Wang; Xiujuan Zang; Yan Hu; Andong Qiu; Shougang Zhuang; Na Liu
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.